Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.48 USD

28.48
11,702,395

-0.04 (-0.14%)

Updated Oct 31, 2024 01:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance

by Zacks Equity Research

Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.

Nalak Das headshot

Markets Melt Down on Profit Taking, Not Economic Logic: 5 Picks

by Nalak Das

We have narrow down the search to five stocks that have provided double-digit returns year to date. These are: HPQ, LKQ, KSS, M and X.

Pfizer (PFE) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $44.71, marking a +0.29% move from the previous day.

DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study

by Zacks Equity Research

DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.

Nalak Das headshot

5 Top-Ranked Large-Cap Stocks That Have Skyrocketed YTD

by Nalak Das

We have narrowed down our search to five large-cap stocks with strong potential for the rest of 2021. These are: NUE, ON, KMX, ORLY and ULTA.

Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well

by Zacks Equity Research

Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.

Will COVID-19 Vaccines for Children be Available by Year-End?

by Zacks Equity Research

The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.

Maharathi Basu headshot

Why U.S. Airline Stocks Gained Yesterday Despite Dim Views

by Maharathi Basu

Stocks like Delta (DAL), American Airlines (AAL) and Southwest (LUV) gain on Thursday despite the Delta variant-induced dull warnings.

Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?

by Zacks Equity Research

Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.

Sweta Killa headshot

ETFs in Focus on Airlines' Slowdown Warnings

by Sweta Killa

The slew of revenue warnings comes with signs of recovery, thereby leading to spike in airline stocks.

Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA

by Zacks Equity Research

Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.

Kinjel Shah headshot

Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs

by Kinjel Shah

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.

Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for USMC

Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study

by Zacks Equity Research

Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.

Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab

by Zacks Equity Research

Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed at $46.51 in the latest trading session, marking a -0.51% move from the prior day.

Sweta Killa headshot

Tap the Nasdaq Rally With These Two Leveraged ETFs

by Sweta Killa

Investors could easily tap the bullish trend by considering a near-term long on the Nasdaq Index with the help of ETFs.

Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study

by Zacks Equity Research

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

Merck's (MRK) Keytruda Gets Nod for Expanded Use in China

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.

Moderna (MRNA) Inks Deal to Develop Ultra-Rare Disease Therapy

by Zacks Equity Research

Moderna (MRNA) inks a collaboration deal with the Institute for Life Changing Medicines to develop a free of charge mRNA-based therapy to treat Crigler-Najjar Syndrome type 1, an ultra-rare disease.

Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca

by Zacks Equity Research

Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca

Kinjel Shah headshot

4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam

by Kinjel Shah

Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage. JNJ, RHHBY, PFE and AZN are worth retaining in your portfolio.

Moderna (MRNA) Seeks Authorization for Booster Dose in Europe

by Zacks Equity Research

Moderna (MRNA) is developing a booster dose of its COVID-19 vaccine, mRNA-1273, for enhancing protection against infection in individuals.

Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies

by Zacks Equity Research

Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.

Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study

by Zacks Equity Research

Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.